Oral KRAS G12D inhibitor GFH375 for previously treated advanced solid tumors with KRASG12D mutations: a phase 1 trial

已完结 10 由给力认识发布于 2026/11/9 15:47:53

DOI:10.1038/s41591-026-04559-4
作者：Xinghao Ai,?Zhengbo Song,?Lin Wu,?Aiping Zhou,?Di Cheng,?Hong Zong,?Heshui Wu,?Zuoxing Niu,?Yuping Sun,?Lingjun Zhu,?Zhiwei Li,?Yanhong Deng,?Ying Yuan,?Xiujuan Qu,?Haitao Zhao,?Yingying Du,?Ziming Li
文献类型：期刊论文
补充材料：只需要正文

Nature

Abstract：Kirsten rat sarcoma viral oncogene homolog (KRAS)G12D is the most prevalent RAS mutation in solid tumors, associated with poor prognosis, and occurs mainly in pancreatic ductal adenocarcinom

应助信息

3小时前

xiuyinglin

02896db8dc1311f1be63208810ba6e4f.pdf 已采纳

3小时前

Book学术机器人

2026/11/9 15:47:54 未找到该文献，机器人已退出，请等待人工下载

2026/11/9 15:47:53 Book学术AI机器人收到请求，开始寻找文献

2026/11/9 15:47:53 已向机器人发送请求

3小时前

给力认识发布求助

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:WileySynergistic Confinement and Passivation Effects Enable High PLQY and Ultrastable CsPbBr3 in Mg-Silicalite-1 for Backlight Displays